AstraZeneca Wilmington R&D Site To Focus On Central Nervous System Drugs
Executive Summary
AstraZeneca's Wilmington, Del. research and development site will focus on developing central nervous system drugs in the restructuring following the merger.
You may also be interested in...
Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.
The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.
Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.
The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.
AstraZeneca Emphasizes Size As Key To Growth In Rx Market
AstraZeneca is guiding investors in the pharmaceutical industry to consider size - both in terms of corporate resources and individual products - as the key to growth.